Diamyd Medical AB (publ) (STO:DMYD.B)
Sweden · Delayed Price · Currency is SEK 1.048
+0.034 (3.35%)
Oct 13, 2026, 4:07 PM CET
Diamyd Medical AB Market Cap
Diamyd Medical AB has a market cap or net worth of 162.42 million as of October 13, 2026. It is the 38,781st most valuable company in the world and the 541st biggest in Sweden. Its market cap has decreased by 89.22% in one year.
Market Cap
162.42M
Enterprise Value
-143.00M
Revenue
477.00K
Global Rank
Country Rank
#541 Sweden
PE Ratio
n/a
ChartMarket Cap Chart
Since May 20, 2013, Diamyd Medical AB's market cap has increased from 132.51M to 162.42M, an increase of 22.57%. That is a compound annual growth rate of 1.53%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 9, 2026 | 151.88M | -90.19% |
| Dec 30, 2025 | 1.55B | -9.52% |
| Dec 30, 2024 | 1.71B | 182.47% |
| Dec 29, 2023 | 605.80M | -41.10% |
| Dec 30, 2022 | 1.03B | -9.66% |
| Dec 30, 2021 | 1.14B | -46.65% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| IRLAB Therapeutics AB | 253.70M |
| Elicera Therapeutics AB | 183.86M |
| Xintela AB | 154.60M |
| Simris Group AB (PUBL) | 150.50M |
| Abera Bioscience AB | 140.62M |
| NextCell Pharma AB | 127.91M |
| Initiator Pharma | 123.22M |
| OncoZenge AB | 115.37M |